COMPASS Pathways (NasdaqGS:CMPS) FY Conference Summary Company Overview - **Company**: COMPASS Pathways - **Ticker**: CMPS - **Focus**: Development of COMP360, a treatment for treatment-resistant depression (TRD) Key Highlights from Phase III Studies Study Designs - **Study 005**: Placebo-controlled, 25 mg COMP360 vs. placebo, 6-week primary endpoint measuring change in MADRS (Montgomery-Åsberg Depression Rating Scale) from baseline after a single administration - **Study 006**: Three arms (10 mg, 25 mg, and 1 mg psilocybin), with two initial administrations three weeks apart, also with a 6-week primary endpoint [2][4] Results - **Study 005**: - 3.6 point difference in MADRS at primary endpoint, statistically significant at all time points [3] - 40% of patients receiving a second administration achieved remission [4] - **Study 006**: - 3.8 point difference between 25 mg and 1 mg active comparator at week 6, statistically significant at all time points [4] Clinical Significance - A clinically meaningful benefit is defined as at least a 25% reduction in MADRS, with 25% of patients in Study 005 and nearly 40% in Study 006 achieving this [9] Incremental Benefits of Dosing - The second dose may provide nuanced benefits, potentially increasing remission rates rather than just mean population MADRS separation [5][6] - The consistency of results across multiple trials suggests a durable response to treatment [21][22] Patient Quality of Life - A 25% reduction in MADRS correlates to significant improvements in daily functioning and quality of life for TRD patients [26][31] Commercial Strategy - The 10 mg dose did not meet clinical relevance at six weeks, but is being explored in PTSD trials [62][65] - The 25 mg dose is the primary focus for launch due to its robust statistical significance [62] FDA Relationship and Regulatory Strategy - The company maintains a strong relationship with the FDA, emphasizing a thorough and robust development process for COMP360 [83][84] - The FDA has encouraged the submission of data on a rolling basis, which may expedite the approval process [88] Safety and Monitoring - The safety profile of COMP360 is favorable, with a low barrier for patients to try the treatment [112] - The treatment model aligns with existing psychiatric care frameworks, utilizing similar facilities and personnel as current treatments like SPRAVATO [124][125] Future Data and Analysis - Additional data on quality of life outcomes and secondary metrics will be analyzed and reported in upcoming conferences [72][73] - Real-world evidence post-approval will help refine patient profiles for predicting treatment response [105][106] Conclusion - COMPASS Pathways is positioned to potentially revolutionize treatment for TRD with COMP360, supported by promising clinical data and a proactive regulatory strategy. The focus on patient quality of life and safety further enhances its commercial viability.